Prelude Therapeutics (PRLD) Competitors

$4.66 +0.02 (+0.43%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$4.66 0.00 (0.00%)

As of 04:05 AM Eastern

PRLD vs. MLTX, MPLT, CMPS, JBIO, and CALT

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include MoonLake Immunotherapeutics (MLTX), Maplight Therapeutics (MPLT), Compass Pathways (CMPS), Jade Biosciences (JBIO), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, MoonLake Immunotherapeutics had 22 more articles in the media than Prelude Therapeutics. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.30 beat MoonLake Immunotherapeutics' score of 0.70 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Prelude Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Prelude Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.18	-$99.50M	-$1.29	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

MoonLake Immunotherapeutics' return on equity of -85.15% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-114.97%	-66.50%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 64.52%. MoonLake Immunotherapeutics has a consensus price target of $23.85, suggesting a potential upside of 29.53%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Prelude Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Prelude Therapeutics beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Prelude Therapeutics has higher revenue and earnings than Maplight Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A
Prelude Therapeutics	$12.14M	24.18	-$99.50M	-$1.29	N/A

Maplight Therapeutics' return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Prelude Therapeutics	N/A	-114.97%	-66.50%

In the previous week, Maplight Therapeutics had 14 more articles in the media than Prelude Therapeutics. MarketBeat recorded 19 mentions for Maplight Therapeutics and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.30 beat Maplight Therapeutics' score of 0.28 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	2 Very Positive mention(s)	9 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics currently has a consensus price target of $34.43, suggesting a potential upside of 12.25%. Prelude Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 64.52%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

79.7% of Prelude Therapeutics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Maplight Therapeutics and Prelude Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Compass Pathways had 5 more articles in the media than Prelude Therapeutics. MarketBeat recorded 10 mentions for Compass Pathways and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.30 beat Compass Pathways' score of 0.97 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways currently has a consensus price target of $20.55, suggesting a potential upside of 87.46%. Prelude Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 64.52%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities research analysts plainly believe Compass Pathways is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has higher revenue and earnings than Compass Pathways. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.09	N/A
Prelude Therapeutics	$12.14M	24.18	-$99.50M	-$1.29	N/A

Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prelude Therapeutics' return on equity of -114.97% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-192.95%	-61.31%
Prelude Therapeutics	N/A	-114.97%	-66.50%

Summary

Compass Pathways beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Prelude Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Prelude Therapeutics	$12.14M	24.18	-$99.50M	-$1.29	N/A

Jade Biosciences' return on equity of -51.34% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Prelude Therapeutics	N/A	-114.97%	-66.50%

In the previous week, Jade Biosciences had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Jade Biosciences and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.30 beat Jade Biosciences' score of 0.07 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Jade Biosciences currently has a consensus target price of $34.33, indicating a potential upside of 36.95%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 64.52%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

79.7% of Prelude Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Prelude Therapeutics beats Jade Biosciences on 8 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Calliditas Therapeutics AB (publ)?

Prelude Therapeutics (NASDAQ:PRLD) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Prelude Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 64.52%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Prelude Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Prelude Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.18	-$99.50M	-$1.29	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Prelude Therapeutics had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Prelude Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Prelude Therapeutics' average media sentiment score of 1.30 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Prelude Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Prelude Therapeutics' return on equity of -114.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-114.97%	-66.50%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Prelude Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$292.33M	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.66	18.86	21.00	25.58
Price / Sales	24.18	289.31	554.55	78.84
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	4.28	4.35	9.75	6.66
Net Income	-$99.50M	$72.19M	$3.55B	$333.63M
7 Day Performance	-9.51%	-1.05%	-0.53%	-0.11%
1 Month Performance	5.91%	-0.02%	1.20%	3.94%
1 Year Performance	416.11%	46.31%	41.22%	36.07%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	4.6861 of 5 stars	$4.66 +0.4%	$7.67 +64.5%	+366.0%	$292.33M	$12.14M	N/A	120	Positive News Earnings Report
MLTX MoonLake Immunotherapeutics	3.4533 of 5 stars	$17.56 0.0%	$23.08 +31.4%	-52.2%	$1.26B	N/A	N/A	2	Trending News Earnings Report Analyst Forecast Analyst Revision
MPLT Maplight Therapeutics	1.9627 of 5 stars	$28.95 +1.2%	$34.43 +18.9%	N/A	$1.23B	N/A	N/A	109	Insider Trade
CMPS Compass Pathways	4.0947 of 5 stars	$9.42 -1.0%	$20.45 +117.1%	+181.0%	$1.22B	N/A	N/A	120	News Coverage Earnings Report Analyst Forecast Gap Up
JBIO Jade Biosciences	2.5216 of 5 stars	$24.56 +0.2%	$31.17 +26.9%	N/A	$1.21B	N/A	N/A	20	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MLTX, MPLT, CMPS, JBIO, and CALT

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Prelude Therapeutics compare to Maplight Therapeutics?

Summary

How does Prelude Therapeutics compare to Compass Pathways?

Summary

How does Prelude Therapeutics compare to Jade Biosciences?

Summary

How does Prelude Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MLTX, MPLT, CMPS, JBIO, and CALT

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Does the media favor PRLD or MLTX?

Do institutionals and insiders hold more shares of PRLD or MLTX?

Which has more risk and volatility, PRLD or MLTX?

Which has higher earnings and valuation, PRLD or MLTX?

Is PRLD or MLTX more profitable?

Do analysts rate PRLD or MLTX?

Summary

How does Prelude Therapeutics compare to Maplight Therapeutics?

Which has higher valuation and earnings, MPLT or PRLD?

Is MPLT or PRLD more profitable?

Does the media favor MPLT or PRLD?

Do analysts recommend MPLT or PRLD?

Do insiders & institutionals hold more shares of MPLT or PRLD?

Summary

How does Prelude Therapeutics compare to Compass Pathways?

Does the media refer more to CMPS or PRLD?

Do analysts recommend CMPS or PRLD?

Which has higher valuation and earnings, CMPS or PRLD?

Which has more volatility and risk, CMPS or PRLD?

Do insiders & institutionals hold more shares of CMPS or PRLD?

Is CMPS or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to Jade Biosciences?

Which has better earnings & valuation, JBIO or PRLD?

Is JBIO or PRLD more profitable?

Does the media refer more to JBIO or PRLD?

Which has more risk and volatility, JBIO or PRLD?

Do analysts recommend JBIO or PRLD?

Do insiders & institutionals have more ownership in JBIO or PRLD?

Summary

How does Prelude Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do analysts recommend PRLD or CALT?

Which has more volatility & risk, PRLD or CALT?

Which has preferable earnings and valuation, PRLD or CALT?

Do institutionals & insiders have more ownership in PRLD or CALT?

Does the media prefer PRLD or CALT?

Is PRLD or CALT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools